Erucamide stood out. Its levels fell steeply as photoreceptors deteriorated, hinting that the drop might actively shape the disease rather than simply mirror the damage.

"That was a pivotal moment for us," co-author Dale Boger, the Richard and Alice Cramer Professor of Chemistry at Scripps Research, recalled. "It raised the possibility that erucamide could be influencing how tissue responds and wasn't just changing as a consequence of disease."

How does erucamide protect the retina?

Restoring erucamide did not directly rescue dying photoreceptors. Instead, the molecule activated CD11b⁺ myeloid cells, immune cells that respond to injury and help maintain tissue throughout the body.

Once activated, those cells released signals tied to neurovascular stabilization, supporting both nerve cells and the blood vessels that feed them. The treatment did not reverse degeneration outright. It slowed certain aspects of the process and preserved the structure of tissue that remained.

The researchers also identified a protein called TMEM19 that erucamide binds to. When they reduced TMEM19 levels, the myeloid cells no longer responded to erucamide, and the protective effects vanished.

Why deliver erucamide with nanoparticles?

Erucamide is hydrophobic — it does not dissolve well in water and tends to clump when injected directly into the eye. Most eye medications, by contrast, are water-based.

To work around this, the team packaged erucamide inside porous silicon nanoparticles, tiny engineered carriers that release their payload gradually. That system kept the molecule stable and spread it more evenly inside the eye.

What could this mean for treatment?

The findings point to a strategy in which a future drug strengthens a defense the eye already uses, rather than introducing an entirely new biological process. The approach could eventually complement therapies for diabetic retinopathy, retinitis pigmentosa, and age-related macular degeneration.

"The goal is to reinforce a signal that's already present," Friedlander noted. "If we can learn how to modulate that response carefully, it could offer a new path for slowing the progression of retinal diseases where treatment options remain limited."

What questions remain?

The team has identified several pieces of the erucamide pathway, but key details remain unknown. Future studies will test how the signal behaves across different retinal diseases and whether manipulating it offers benefits over longer periods.

Turning the molecule into a drug will also require work. Researchers plan to test modified forms of erucamide that may produce stronger or longer-lasting effects, and to examine related lipids that might work even better.

First author Guoqin Wei, a staff scientist at Scripps Research who began the project seven years earlier as a postdoctoral associate in Friedlander's lab, framed the discovery as a shift in perspective.

"Instead of targeting the photoreceptors themselves, erucamide appears to work by engaging the surrounding environment," Wei explained. "That shift in perspective could be important for treating degenerative retinal diseases going forward."